Brought to you by 
Eli Lilly, Transition Therapeutics enter diabetes partnership, deal ends
25 Jul 2013
Executive Summary
Transition Therapeutics (neurological and metabolic diseases) has granted Eli Lilly exclusive worldwide development and commercialization rights to its gastrin-based therapies for diabetes, including TT223.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eli Lilly, Transition Therapeutics enter diabetes partnership, deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice